Meta-analysis of piperazine ferulate combined with angiotensin receptor antagonist in the treatment of diabetic kidney disease

Objective To system atically evaluate the effectiveness and safety of piperazine ferulate combined with angiotensin receptor antagonist in the treatment of diabetic kidney disease.Methods CNKI,Wan Fang,VIP,CBM,PubMed,EMbase and the Cochrane Li-brary databases were searched by computer.Randomized controlled trials(RCTs)of piperazine ferulate combined with angiotensin receptor antogonist in the treatment of diabetic kidney disease were collected.The retrieval time period was from the establishment of the database to July 2019.Two researchers independently screened literature,extracted data,evaluated risk bias,then,and did meta-analysis,by using stata14.0 software.Results A total of 16 RCTs were enrolled,including 1580 patients with diabetic kidney disease.Meta-analysis showed that,piperazine ferulate combined with angiotensin receptor antagonist could significantly improve the total effectiveness rate of treatmentRR=1.230,95%CI(1.164,1.300),P<0.01,and also significantly reduce 24-hour urine total protein MD=-0.129,95%CI(-0.169,-0.089),P<0.01,serum creatinine MD=-7.340,95%CI(-9.935,-4.745),P<0.01,urinary albumin excretion rateMD=-18.985,95%CI(-31.778,-6.192),P<0.01,blood urea nitrogen MD=-0.890,95%CI(-1.548,-0.231),P<0.01,and urine β2-microglobin MD=-0.190,95%CI(-0.234,-0.146),P<0.01.In the aspect of safety,the differences in the incidences of dizziness,nausea,abdominal pain and other adverse events between the two groups were none of statistical significance.Conclusions The current limited evidence indicates that piperazine ferulate can significantly improve the clinical efficacy of diabetic kidney disease,and has high safety, on the basis of the routine treatment.Due to the limitation of the quantity and quality of the included studies,the above conclusion needs to be verified by more high-quality studies.